Literature DB >> 29168583

Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.

Seung Ha Lee1, Hanna Cho1, Jae Yong Choi2,3, Jae Hoon Lee2, Young Hoon Ryu2, Myung Sik Lee1, Chul Hyoung Lyoo1.   

Abstract

BACKGROUND: In addition to Lewy body pathology, amyloid-β plaques and neurofibrillary tangles that are characteristic for Alzheimer's disease are also frequently found in Lewy body diseases.
OBJECTIVES: The objective of this study was to investigate tau accumulation patterns in dementia with Lewy bodies and other Lewy body diseases using in vivo 18 F-AV-1451 PET.
METHODS: The study included 12 Parkinson's disease (PD) patients with normal cognition, 22 PD patients with cognitive impairment, and 18 dementia with Lewy bodies patients. In addition, 25 Alzheimer's disease patients and 25 healthy controls were included for comparison. All participants underwent 18 F-AV-1451 and 18 F-florbetaben PET scans, and cortical binding values were compared between the controls and each disease group.
RESULTS: When compared with the controls, dementia with Lewy bodies patients showed slightly increased 18 F-AV-1451 binding in the primary sensorimotor and visual cortices and the parieto-temporal cortices, which failed to survive multiple comparisons. Amyloid-positive dementia with Lewy bodies patients showed significantly increased binding in the same regions when compared with controls, and even greater binding in the primary sensorimotor and visual cortices than Alzheimer's disease. Meanwhile, binding in the lateral and medial temporal cortices was less prominent than in Alzheimer's disease. In dementia with Lewy bodies, 18 F-AV-1451 binding in the occipital cortex correlated with 18 F-florbetaben binding. Amyloid-negative patients with normal cognition, patients with cognitive impairment, and dementia with Lewy bodies patients did not show increased 18 F-AV-1451 binding.
CONCLUSIONS: Dementia with Lewy bodies patients may harbor 18 F-AV-1451 binding patterns distinct from Alzheimer's disease, with greater involvement of the primary cortices and less involvement of the temporal cortex. Tau burden increases in the Lewy body disease spectrum, and amyloid may play an important role in the accumulation of neocortical tau in Lewy body diseases.
© 2017 International Parkinson and Movement Disorder Society. © 2017 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  18F-AV-1451; tau; positron emission tomography; Lewy body disease; dementia with Lewy bodies

Mesh:

Substances:

Year:  2017        PMID: 29168583     DOI: 10.1002/mds.27252

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

Review 1.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

2.  Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-29       Impact factor: 3.575

Review 3.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

Review 4.  Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views.

Authors:  Prabesh Kanel; Marc-André Bedard; Meghmik Aghourian; Pedro Rosa-Neto; Jean-Paul Soucy; Roger L Albin; Nicolaas I Bohnen
Journal:  Curr Neurol Neurosci Rep       Date:  2021-09-20       Impact factor: 6.030

Review 5.  The Role of Tau Imaging in Parkinsonian Disorders.

Authors:  Jochen Hammes; Alexander Drzezga; Thilo van Eimeren
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-06       Impact factor: 5.081

Review 6.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

7.  Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography.

Authors:  Elijah Mak; Nicolas Nicastro; Maura Malpetti; George Savulich; Ajenthan Surendranathan; Negin Holland; Luca Passamonti; P Simon Jones; Stephen F Carter; Li Su; Young T Hong; Tim D Fryer; Guy B Williams; Franklin Aigbirhio; James B Rowe; John T O'Brien
Journal:  Neurobiol Aging       Date:  2020-11-14       Impact factor: 4.673

8.  Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease.

Authors:  D G Coughlin; R Ittyerah; C Peterson; J S Phillips; S Miller; K Rascovsky; D Weintraub; A D Siderowf; J E Duda; H I Hurtig; D A Wolk; C T McMillan; P A Yushkevich; M Grossman; E B Lee; J Q Trojanowski; D J Irwin
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-24       Impact factor: 8.090

9.  β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.

Authors:  Daniel Ferreira; Scott A Przybelski; Timothy G Lesnick; Afina W Lemstra; Elisabet Londos; Frederic Blanc; Zuzana Nedelska; Christopher G Schwarz; Jonathan Graff-Radford; Matthew L Senjem; Julie A Fields; David S Knopman; Rodolfo Savica; Tanis J Ferman; Neill R Graff-Radford; Val J Lowe; Clifford R Jack; Ronald C Petersen; Brit Mollenhauer; Sara Garcia-Ptacek; Carla Abdelnour; Jakub Hort; Laura Bonanni; Ketil Oppedal; Milica G Kramberger; Bradley F Boeve; Dag Aarsland; Eric Westman; Kejal Kantarci
Journal:  Neurology       Date:  2020-09-28       Impact factor: 9.910

10.  Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.

Authors:  David G Coughlin; Jeffrey S Phillips; Emily Roll; Claire Peterson; Rebecca Lobrovich; Katya Rascovsky; Molly Ungrady; David A Wolk; Sandhitsu Das; Daniel Weintraub; Edward B Lee; John Q Trojanowski; Leslie M Shaw; Sanjeev Vaishnavi; Andrew Siderowf; Ilya M Nasrallah; David J Irwin; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2020-08-21       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.